CAR-T cell therapy represents a transformative immunotherapy approach for relapsed or refractory blood cancers, requiring specialized infrastructure, experienced hematology-oncology teams, and rigorous toxicity management protocols that only a select group of hospitals in India currently provide. TL;DR India's CAR-T therapy landscape includes indigenous NexCAR19 and Qartemi products achieving 70-83% response rates in clinical trials, with costs of ₹30-50 lakhs versus ₹3-4 cro

🧠 TL;DR Trastuzumab Deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) Combines targeting + chemotherapy in one molecule Used in HER2-positive and HER2-low breast cancer, gastric & some lung cancers Given once every 3 weeks (half-life ~6 days) ❌ NOT the same as trastuzumab (Herceptin) or T-DM1 → common dangerous confusion ⚠️ Major risks: lung toxicity (ILD), heart dysfunction, bone marrow suppression 💰 Cost varies widely → depends on weight, schemes & support progr

🧠 TL;DR Daratumumab is a CD38-targeted immunotherapy used in multiple myeloma and amyloidosis Not every patient needs it immediately-timing is critical Infusion reactions can occur in up to 50% patients initially, but are manageable It interferes with blood tests (Coombs test & protein electrophoresis) Dose does NOT need adjustment in kidney failure or dialysis Cost is typically ₹2–3 lakh/month, but varies due to support programs Many patients consult me to decide whether th

🧠 TL;DR Nivolumab is a PD-1 immunotherapy that activates your immune system against cancer Used in lung, head & neck, esophagus, melanoma, kidney, lymphoma, colorectal (MSI-high) Long-acting (~26 days) → small delays are usually safe Side effects are immune-related (not infection-related) Timing of side effects gives major diagnostic clues Can be used safely in kidney failure, dialysis, liver dysfunction (non-immune) Cost in India has dropped from ₹4.5 lakh → ~₹1 lakh/month

CAR-T cell therapy represents a breakthrough immunotherapy for relapsed and refractory blood cancers, now accessible in India at a fraction of global costs, making advanced cancer treatment available to patients who previously had limited options. TL;DR India's CAR-T cell therapy costs Rs 30-40 lakhs compared to Rs 3-4 crore internationally, representing 90% savings for patients [2] Indigenous therapies like NexCAR19 have demonstrated a 70% overall response rate in clinical t

TL;DR Pi Cancer Care by Dr. Bharat Patodiya in Hyderabad offers comprehensive lymphoma treatment with CAR-T therapy evaluation, costing ₹35-45 lakhs compared to ₹3-4 crores internationally—an 80% cost reduction [3] India now has two FDA-approved CAR-T therapies (NexCAR19 and Qartemi) achieving 70-83% response rates in clinical trials, with recent advances showing 83.3% overall response rates [1] [6] Leading treatment centers include Pi Cancer Care, Tata Memorial Hospital, HCG

TL;DR Pi Cancer Care by Dr. Bharat Patodiya leads personalized cancer treatment in India with 80-85% success rates and European-trained expertise from University of ULM Germany and University of Zurich Switzerland India's top 10 cancer hospitals include Tata Memorial Hospital (established 1941), AIIMS New Delhi, and Apollo Cancer Centre with proton therapy achieving up to 95% success rates for select cancers [4] Treatment costs in India are 60-80% lower than Western countries